Prediction and prognostic importance of in-hospital major bleeding in a real-world cohort of patients with pulmonary embolism.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 09 2019
Historique:
received: 17 09 2018
revised: 15 02 2019
accepted: 11 03 2019
pubmed: 29 3 2019
medline: 8 5 2020
entrez: 29 3 2019
Statut: ppublish

Résumé

Assessment of bleeding risk in patients with pulmonary embolism (PE) is challenging. Recently, the VTE-BLEED score was shown to predict major bleeding. Therefore, we aimed to investigate the VTE-BLEED score and assess the prognostic impact of major bleeding in a real-world cohort of PE patients. Consecutive PE patients included in a prospective single-center cohort study between 09/2008 and 11/2016 were eligible for analysis; patients treated with thrombolysis were excluded. The VTE-BLEED was calculated post-hoc; in-hospital major bleeding was defined using the ISTH definition. Overall, 522 patients (median age 69, IQR 56-78 years; 53% female) were included in the present analysis; major bleeding occurred in 18 (3.5%) patients. A VTE-BLEED score ≥2 points identified patients at high-risk for major bleeding (OR 3.7, 95% CI 1.1-13.0, sensitivity 83%, specificity 42%). Additionally, a GFR <30 ml/min/1.73 m In a real-world cohort, the VTE-BLEED score identified PE patients at risk for in-hospital major bleeding. However, for assessment of bleeding risk, renal function and previous surgery should be considered. Major bleeding emerged as strong predictor of in-hospital and 1-year mortality.

Sections du résumé

BACKGROUND
Assessment of bleeding risk in patients with pulmonary embolism (PE) is challenging. Recently, the VTE-BLEED score was shown to predict major bleeding. Therefore, we aimed to investigate the VTE-BLEED score and assess the prognostic impact of major bleeding in a real-world cohort of PE patients.
METHODS
Consecutive PE patients included in a prospective single-center cohort study between 09/2008 and 11/2016 were eligible for analysis; patients treated with thrombolysis were excluded. The VTE-BLEED was calculated post-hoc; in-hospital major bleeding was defined using the ISTH definition.
RESULTS
Overall, 522 patients (median age 69, IQR 56-78 years; 53% female) were included in the present analysis; major bleeding occurred in 18 (3.5%) patients. A VTE-BLEED score ≥2 points identified patients at high-risk for major bleeding (OR 3.7, 95% CI 1.1-13.0, sensitivity 83%, specificity 42%). Additionally, a GFR <30 ml/min/1.73 m
CONCLUSIONS
In a real-world cohort, the VTE-BLEED score identified PE patients at risk for in-hospital major bleeding. However, for assessment of bleeding risk, renal function and previous surgery should be considered. Major bleeding emerged as strong predictor of in-hospital and 1-year mortality.

Identifiants

pubmed: 30917899
pii: S0167-5273(18)34801-0
doi: 10.1016/j.ijcard.2019.03.017
pii:
doi:

Types de publication

Journal Article Pragmatic Clinical Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-149

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Karl-Patrik Kresoja (KP)

Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité - University Medicine, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Cardiovascular Research Centre (DZHK), partner site Berlin, Germany.

Matthias Ebner (M)

Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité - University Medicine, Berlin, Germany; German Cardiovascular Research Centre (DZHK), partner site Berlin, Germany.

Nina I J Rogge (NIJ)

Clinic of Cardiology and Pneumology, Heart Center, University Medical Center Goettingen, Germany.

Carmen Sentler (C)

Clinic of Cardiology and Pneumology, Heart Center, University Medical Center Goettingen, Germany.

Karsten Keller (K)

Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany.

Lukas Hobohm (L)

Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Center for Cardiology, Cardiology I, University Medical Center Mainz, Germany.

Gerd Hasenfuß (G)

Clinic of Cardiology and Pneumology, Heart Center, University Medical Center Goettingen, Germany; German Cardiovascular Research Centre (DZHK), partner site Goettingen, Germany.

Stavros V Konstantinides (SV)

Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany; Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece.

Burkert Pieske (B)

Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité - University Medicine, Berlin, Germany; Berlin Institute of Health, Berlin, Germany; German Cardiovascular Research Centre (DZHK), partner site Berlin, Germany.

Mareike Lankeit (M)

Department of Internal Medicine and Cardiology, Campus Virchow Klinikum (CVK), Charité - University Medicine, Berlin, Germany; German Cardiovascular Research Centre (DZHK), partner site Berlin, Germany; Clinic of Cardiology and Pneumology, Heart Center, University Medical Center Goettingen, Germany; Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany. Electronic address: mareike.lankeit@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH